Sugi Predict

Sugi Predict / Compounds / SCHEMBL5142275

SCHEMBL5142275

SCHEMBL5142275

COC(=O)c1c(I)cc(I)c(OC)c1I

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TPMT P51580 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ CYP3A4 P08684 2/20 0.39
▸ HPGD P15428 2/20 0.39
▸ CA12 O43570 2/20 0.38
▸ CA1 P00915 2/20 0.38
▸ CA2 P00918 2/20 0.38
▸ CA7 P43166 2/20 0.38
▸ CA9 Q16790 2/20 0.38
▸ CA14 Q9ULX7 2/20 0.38
▸ KDM4E B2RXH2 6/20 0.38
▸ POLB P06746 4/20 0.38
▸ ACHE P22303 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.35
▸ USP2 O75604 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ CISD2 Q8N5K1 2/20 0.35
▸ CFTR P13569 1/20 0.34
▸ LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5144379 0.83 TPMT (0.51) TPMTSMN1; SMN2CYP3A4HPGDCA12
SCHEMBL28875483 0.83 HCRTR1 (0.35) TPMTCYP3A4HPGDCA12CA1
SCHEMBL5142250 0.81 TPMT (0.42) TPMTKDM4EALDH1A1HSD17B10GAA
SCHEMBL31068449 0.79 CA12 (0.44) CYP3A4HPGDCA12CA1CA2
SCHEMBL27922079 0.79 CA12 (0.44) CYP3A4HPGDCA12CA1CA2
SCHEMBL9387753 0.78 CFTR (0.41) CYP3A4HPGDCA12CA1CA2
SCHEMBL11713096 0.76 TSHR (0.41) CYP3A4HPGDCA12CA1CA2
SCHEMBL14024231 0.75 TPMT (0.65) TPMTCYP3A4HPGDCA12CA1
SCHEMBL25477911 0.74 CA12 (0.45) CYP3A4HPGDCA12CA1CA2
SCHEMBL5146023 0.74 TPMT (0.36) TPMTCYP3A4HPGDKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1423136-A4 POLYPEPTIDE CONJUGATES WITH EXTENDED CIRCULATING HALF-LIVES EPIX PHARM INC (US) 2007-07-25 — — EP disclosed
US-7186797-B2 Polypeptide conjugates with extended circulating half-lives EPIX PHARMACEUTICALS, INC. (US) 2007-03-06 — — US disclosed
US-7186797-B2 Polypeptide conjugates with extended circulating half-lives EPIX PHARMACEUTICALS, INC. (US) 2007-03-06 — — US disclosed
US-7186797-B2 Polypeptide conjugates with extended circulating half-lives EPIX PHARMACEUTICALS, INC. (US) 2007-03-06 — — US disclosed
US-20040254119-A1 Polypeptide conjugates with extended circulating half-lives EPIX PHARMACEUTICALS, INC. 2004-12-16 — — US disclosed
EP-1423136-A1 POLYPEPTIDE CONJUGATES WITH EXTENDED CIRCULATING HALF-LIVES Epix Medical, Inc. (US) 2004-06-02 — — EP disclosed
WO-2003013573-A1 POLYPEPTIDE CONJUGATES WITH EXTENDED CIRCULATING HALF-LIVES EPIX MEDICAL, INC. (US) 2003-02-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254119-A1 Polypeptide conjugates with extended circulating half-lives ALB, TTR, SHBG TPMT 3599/4885SMN1; SMN2 1406/4885CYP3A4 1346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.